nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—PGR—multiple sclerosis	0.263	0.781	CbGaD
Norethindrone—ALB—multiple sclerosis	0.0738	0.219	CbGaD
Norethindrone—PGR—Betamethasone—multiple sclerosis	0.0693	0.25	CbGbCtD
Norethindrone—PGR—Dexamethasone—multiple sclerosis	0.0403	0.146	CbGbCtD
Norethindrone—Danazol—Prednisone—multiple sclerosis	0.0234	0.0756	CrCrCtD
Norethindrone—Cortisone acetate—Methylprednisolone—multiple sclerosis	0.0217	0.0698	CrCrCtD
Norethindrone—Cortisone acetate—Prednisone—multiple sclerosis	0.0198	0.0637	CrCrCtD
Norethindrone—Cortisone acetate—Prednisolone—multiple sclerosis	0.0193	0.0622	CrCrCtD
Norethindrone—Fluoxymesterone—Betamethasone—multiple sclerosis	0.019	0.0613	CrCrCtD
Norethindrone—Fluoxymesterone—Dexamethasone—multiple sclerosis	0.019	0.0613	CrCrCtD
Norethindrone—Fluoxymesterone—Triamcinolone—multiple sclerosis	0.0186	0.0599	CrCrCtD
Norethindrone—Fluoxymesterone—Prednisolone—multiple sclerosis	0.0172	0.0554	CrCrCtD
Norethindrone—Progesterone—Prednisolone—multiple sclerosis	0.0168	0.054	CrCrCtD
Norethindrone—Methyltestosterone—Prednisone—multiple sclerosis	0.0167	0.0539	CrCrCtD
Norethindrone—Methyltestosterone—Prednisolone—multiple sclerosis	0.0163	0.0527	CrCrCtD
Norethindrone—Hydrocortisone—Methylprednisolone—multiple sclerosis	0.0153	0.0494	CrCrCtD
Norethindrone—Hydrocortisone—Betamethasone—multiple sclerosis	0.0151	0.0487	CrCrCtD
Norethindrone—Hydrocortisone—Dexamethasone—multiple sclerosis	0.0151	0.0487	CrCrCtD
Norethindrone—Hydrocortisone—Triamcinolone—multiple sclerosis	0.0148	0.0476	CrCrCtD
Norethindrone—ALB—Prednisone—multiple sclerosis	0.0147	0.0531	CbGbCtD
Norethindrone—Testosterone—Prednisolone—multiple sclerosis	0.0145	0.0469	CrCrCtD
Norethindrone—Hydrocortisone—Prednisone—multiple sclerosis	0.014	0.0451	CrCrCtD
Norethindrone—Hydrocortisone—Prednisolone—multiple sclerosis	0.0137	0.044	CrCrCtD
Norethindrone—ABCB1—Methylprednisolone—multiple sclerosis	0.0127	0.0458	CbGbCtD
Norethindrone—CYP3A4—Fingolimod—multiple sclerosis	0.0118	0.0426	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.00981	0.0355	CbGbCtD
Norethindrone—CYP3A7—Dexamethasone—multiple sclerosis	0.00981	0.0355	CbGbCtD
Norethindrone—CYP2C19—Prednisone—multiple sclerosis	0.00951	0.0344	CbGbCtD
Norethindrone—ABCB1—Mitoxantrone—multiple sclerosis	0.00924	0.0334	CbGbCtD
Norethindrone—ABCB1—Betamethasone—multiple sclerosis	0.00824	0.0298	CbGbCtD
Norethindrone—ABCB1—Prednisolone—multiple sclerosis	0.00813	0.0294	CbGbCtD
Norethindrone—ABCB1—Prednisone—multiple sclerosis	0.00768	0.0278	CbGbCtD
Norethindrone—CYP3A4—Methylprednisolone—multiple sclerosis	0.00759	0.0275	CbGbCtD
Norethindrone—CYP3A5—Dexamethasone—multiple sclerosis	0.00736	0.0266	CbGbCtD
Norethindrone—ALB—Methotrexate—multiple sclerosis	0.00736	0.0266	CbGbCtD
Norethindrone—CYP2C19—Dexamethasone—multiple sclerosis	0.00594	0.0215	CbGbCtD
Norethindrone—CYP3A4—Triamcinolone—multiple sclerosis	0.00575	0.0208	CbGbCtD
Norethindrone—CYP3A4—Mitoxantrone—multiple sclerosis	0.00554	0.02	CbGbCtD
Norethindrone—CYP3A4—Betamethasone—multiple sclerosis	0.00494	0.0179	CbGbCtD
Norethindrone—CYP3A4—Prednisolone—multiple sclerosis	0.00487	0.0176	CbGbCtD
Norethindrone—ABCB1—Dexamethasone—multiple sclerosis	0.00479	0.0173	CbGbCtD
Norethindrone—CYP3A4—Prednisone—multiple sclerosis	0.0046	0.0166	CbGbCtD
Norethindrone—ABCB1—Methotrexate—multiple sclerosis	0.00385	0.0139	CbGbCtD
Norethindrone—CYP3A4—Dexamethasone—multiple sclerosis	0.00287	0.0104	CbGbCtD
Norethindrone—Ethynodiol—PGR—multiple sclerosis	0.00038	0.116	CrCbGaD
Norethindrone—Norelgestromin—PGR—multiple sclerosis	0.000359	0.109	CrCbGaD
Norethindrone—Allylestrenol—PGR—multiple sclerosis	0.000359	0.109	CrCbGaD
Norethindrone—Desogestrel—PGR—multiple sclerosis	0.000346	0.105	CrCbGaD
Norethindrone—Norgestimate—PGR—multiple sclerosis	0.000324	0.0982	CrCbGaD
Norethindrone—Danazol—CCL2—multiple sclerosis	0.000296	0.0899	CrCbGaD
Norethindrone—Etonogestrel—PGR—multiple sclerosis	0.00028	0.085	CrCbGaD
Norethindrone—Drospirenone—PGR—multiple sclerosis	0.000243	0.0737	CrCbGaD
Norethindrone—Levonorgestrel—PGR—multiple sclerosis	0.000198	0.0601	CrCbGaD
Norethindrone—Danazol—PGR—multiple sclerosis	0.00018	0.0548	CrCbGaD
Norethindrone—Skin disorder—Cladribine—multiple sclerosis	0.000168	0.00249	CcSEcCtD
Norethindrone—Drospirenone—BCHE—multiple sclerosis	0.000166	0.0505	CrCbGaD
Norethindrone—Mood swings—Triamcinolone—multiple sclerosis	0.000166	0.00245	CcSEcCtD
Norethindrone—Abdominal distension—Prednisolone—multiple sclerosis	0.000165	0.00244	CcSEcCtD
Norethindrone—Mood swings—Methylprednisolone—multiple sclerosis	0.000165	0.00244	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Dexamethasone—multiple sclerosis	0.000164	0.00242	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Betamethasone—multiple sclerosis	0.000164	0.00242	CcSEcCtD
Norethindrone—Haemoglobin—Mitoxantrone—multiple sclerosis	0.000161	0.00238	CcSEcCtD
Norethindrone—Haemorrhage—Mitoxantrone—multiple sclerosis	0.00016	0.00237	CcSEcCtD
Norethindrone—Hepatitis—Mitoxantrone—multiple sclerosis	0.00016	0.00237	CcSEcCtD
Norethindrone—Thrombophlebitis—Prednisone—multiple sclerosis	0.00016	0.00236	CcSEcCtD
Norethindrone—Pulmonary embolism—Methotrexate—multiple sclerosis	0.000159	0.00235	CcSEcCtD
Norethindrone—Breast disorder—Methylprednisolone—multiple sclerosis	0.000158	0.00233	CcSEcCtD
Norethindrone—Insomnia—Cladribine—multiple sclerosis	0.000157	0.00231	CcSEcCtD
Norethindrone—Migraine—Betamethasone—multiple sclerosis	0.000156	0.00231	CcSEcCtD
Norethindrone—Affect lability—Dexamethasone—multiple sclerosis	0.000156	0.00231	CcSEcCtD
Norethindrone—Affect lability—Betamethasone—multiple sclerosis	0.000156	0.00231	CcSEcCtD
Norethindrone—Migraine—Dexamethasone—multiple sclerosis	0.000156	0.00231	CcSEcCtD
Norethindrone—Somnolence—Cladribine—multiple sclerosis	0.000154	0.00228	CcSEcCtD
Norethindrone—Abdominal distension—Triamcinolone—multiple sclerosis	0.000152	0.00225	CcSEcCtD
Norethindrone—Abdominal distension—Methylprednisolone—multiple sclerosis	0.000152	0.00224	CcSEcCtD
Norethindrone—Mood swings—Betamethasone—multiple sclerosis	0.00015	0.00222	CcSEcCtD
Norethindrone—Mood swings—Dexamethasone—multiple sclerosis	0.00015	0.00222	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00015	0.00221	CcSEcCtD
Norethindrone—Weight increased—Prednisolone—multiple sclerosis	0.00015	0.00221	CcSEcCtD
Norethindrone—Fatigue—Cladribine—multiple sclerosis	0.000149	0.00221	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000146	0.00216	CcSEcCtD
Norethindrone—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.000144	0.00213	CcSEcCtD
Norethindrone—Myocardial infarction—Prednisolone—multiple sclerosis	0.000144	0.00212	CcSEcCtD
Norethindrone—Purpura—Prednisone—multiple sclerosis	0.000143	0.00212	CcSEcCtD
Norethindrone—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000142	0.00209	CcSEcCtD
Norethindrone—Alopecia—Mitoxantrone—multiple sclerosis	0.000142	0.00209	CcSEcCtD
Norethindrone—Urticaria—Cladribine—multiple sclerosis	0.000138	0.00203	CcSEcCtD
Norethindrone—Weight increased—Triamcinolone—multiple sclerosis	0.000138	0.00203	CcSEcCtD
Norethindrone—Weight increased—Methylprednisolone—multiple sclerosis	0.000137	0.00203	CcSEcCtD
Norethindrone—Abdominal pain—Cladribine—multiple sclerosis	0.000137	0.00202	CcSEcCtD
Norethindrone—Skin disorder—Azathioprine—multiple sclerosis	0.000137	0.00202	CcSEcCtD
Norethindrone—Affect lability—Prednisone—multiple sclerosis	0.000136	0.00201	CcSEcCtD
Norethindrone—Thrombophlebitis—Methotrexate—multiple sclerosis	0.000133	0.00197	CcSEcCtD
Norethindrone—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.000133	0.00196	CcSEcCtD
Norethindrone—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.000133	0.00196	CcSEcCtD
Norethindrone—Haemoglobin—Prednisolone—multiple sclerosis	0.000132	0.00195	CcSEcCtD
Norethindrone—Myocardial infarction—Triamcinolone—multiple sclerosis	0.000132	0.00195	CcSEcCtD
Norethindrone—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.000132	0.00195	CcSEcCtD
Norethindrone—Haemorrhage—Prednisolone—multiple sclerosis	0.000132	0.00194	CcSEcCtD
Norethindrone—Photosensitivity—Methotrexate—multiple sclerosis	0.000132	0.00194	CcSEcCtD
Norethindrone—Mood swings—Prednisone—multiple sclerosis	0.000131	0.00193	CcSEcCtD
Norethindrone—Hypersensitivity—Cladribine—multiple sclerosis	0.000128	0.00189	CcSEcCtD
Norethindrone—Weight increased—Betamethasone—multiple sclerosis	0.000125	0.00184	CcSEcCtD
Norethindrone—Weight increased—Dexamethasone—multiple sclerosis	0.000125	0.00184	CcSEcCtD
Norethindrone—Asthenia—Cladribine—multiple sclerosis	0.000124	0.00184	CcSEcCtD
Norethindrone—Pruritus—Cladribine—multiple sclerosis	0.000123	0.00181	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000122	0.0018	CcSEcCtD
Norethindrone—Haemoglobin—Triamcinolone—multiple sclerosis	0.000122	0.0018	CcSEcCtD
Norethindrone—Haemoglobin—Methylprednisolone—multiple sclerosis	0.000121	0.00179	CcSEcCtD
Norethindrone—Haemorrhage—Triamcinolone—multiple sclerosis	0.000121	0.00179	CcSEcCtD
Norethindrone—Convulsion—Mitoxantrone—multiple sclerosis	0.000121	0.00179	CcSEcCtD
Norethindrone—Haemorrhage—Methylprednisolone—multiple sclerosis	0.000121	0.00178	CcSEcCtD
Norethindrone—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.000121	0.00178	CcSEcCtD
Norethindrone—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.000121	0.00178	CcSEcCtD
Norethindrone—Abdominal distension—Prednisone—multiple sclerosis	0.00012	0.00178	CcSEcCtD
Norethindrone—Myocardial infarction—Dexamethasone—multiple sclerosis	0.00012	0.00177	CcSEcCtD
Norethindrone—Myocardial infarction—Betamethasone—multiple sclerosis	0.00012	0.00177	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Methotrexate—multiple sclerosis	0.000119	0.00176	CcSEcCtD
Norethindrone—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000119	0.00175	CcSEcCtD
Norethindrone—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000115	0.0017	CcSEcCtD
Norethindrone—Dizziness—Cladribine—multiple sclerosis	0.000115	0.00169	CcSEcCtD
Norethindrone—Oedema—Mitoxantrone—multiple sclerosis	0.000114	0.00168	CcSEcCtD
Norethindrone—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000114	0.00168	CcSEcCtD
Norethindrone—Abdominal pain—Azathioprine—multiple sclerosis	0.000111	0.00164	CcSEcCtD
Norethindrone—Skin disorder—Mitoxantrone—multiple sclerosis	0.000111	0.00163	CcSEcCtD
Norethindrone—Haemoglobin—Betamethasone—multiple sclerosis	0.00011	0.00163	CcSEcCtD
Norethindrone—Haemoglobin—Dexamethasone—multiple sclerosis	0.00011	0.00163	CcSEcCtD
Norethindrone—Vomiting—Cladribine—multiple sclerosis	0.00011	0.00163	CcSEcCtD
Norethindrone—Haemorrhage—Dexamethasone—multiple sclerosis	0.00011	0.00162	CcSEcCtD
Norethindrone—Haemorrhage—Betamethasone—multiple sclerosis	0.00011	0.00162	CcSEcCtD
Norethindrone—Mood swings—Methotrexate—multiple sclerosis	0.000109	0.00162	CcSEcCtD
Norethindrone—Rash—Cladribine—multiple sclerosis	0.000109	0.00161	CcSEcCtD
Norethindrone—Dermatitis—Cladribine—multiple sclerosis	0.000109	0.00161	CcSEcCtD
Norethindrone—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000109	0.00161	CcSEcCtD
Norethindrone—Weight increased—Prednisone—multiple sclerosis	0.000109	0.0016	CcSEcCtD
Norethindrone—Headache—Cladribine—multiple sclerosis	0.000109	0.0016	CcSEcCtD
Norethindrone—Depression—Prednisone—multiple sclerosis	0.000106	0.00157	CcSEcCtD
Norethindrone—Mental disorder—Methylprednisolone—multiple sclerosis	0.000106	0.00156	CcSEcCtD
Norethindrone—Acute coronary syndrome—Prednisone—multiple sclerosis	0.000105	0.00155	CcSEcCtD
Norethindrone—Myocardial infarction—Prednisone—multiple sclerosis	0.000104	0.00154	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—multiple sclerosis	0.000104	0.00154	CcSEcCtD
Norethindrone—Hypersensitivity—Azathioprine—multiple sclerosis	0.000104	0.00153	CcSEcCtD
Norethindrone—Nausea—Cladribine—multiple sclerosis	0.000103	0.00152	CcSEcCtD
Norethindrone—Somnolence—Mitoxantrone—multiple sclerosis	0.000101	0.0015	CcSEcCtD
Norethindrone—Dyspepsia—Mitoxantrone—multiple sclerosis	0.0001	0.00148	CcSEcCtD
Norethindrone—Convulsion—Prednisolone—multiple sclerosis	9.92e-05	0.00147	CcSEcCtD
Norethindrone—Fatigue—Mitoxantrone—multiple sclerosis	9.82e-05	0.00145	CcSEcCtD
Norethindrone—Alopecia—Betamethasone—multiple sclerosis	9.7e-05	0.00143	CcSEcCtD
Norethindrone—Alopecia—Dexamethasone—multiple sclerosis	9.7e-05	0.00143	CcSEcCtD
Norethindrone—Haemoglobin—Prednisone—multiple sclerosis	9.61e-05	0.00142	CcSEcCtD
Norethindrone—Haemorrhage—Prednisone—multiple sclerosis	9.56e-05	0.00141	CcSEcCtD
Norethindrone—Connective tissue disorder—Prednisone—multiple sclerosis	9.39e-05	0.00139	CcSEcCtD
Norethindrone—Progesterone—PGR—multiple sclerosis	9.35e-05	0.0284	CrCbGaD
Norethindrone—Oedema—Prednisolone—multiple sclerosis	9.35e-05	0.00138	CcSEcCtD
Norethindrone—Anaphylactic shock—Prednisolone—multiple sclerosis	9.35e-05	0.00138	CcSEcCtD
Norethindrone—Dizziness—Azathioprine—multiple sclerosis	9.32e-05	0.00138	CcSEcCtD
Norethindrone—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	9.32e-05	0.00138	CcSEcCtD
Norethindrone—Convulsion—Triamcinolone—multiple sclerosis	9.13e-05	0.00135	CcSEcCtD
Norethindrone—Photosensitivity reaction—Methotrexate—multiple sclerosis	9.11e-05	0.00135	CcSEcCtD
Norethindrone—Convulsion—Methylprednisolone—multiple sclerosis	9.1e-05	0.00134	CcSEcCtD
Norethindrone—Urticaria—Mitoxantrone—multiple sclerosis	9.05e-05	0.00134	CcSEcCtD
Norethindrone—Abdominal pain—Mitoxantrone—multiple sclerosis	9.01e-05	0.00133	CcSEcCtD
Norethindrone—Vomiting—Azathioprine—multiple sclerosis	8.96e-05	0.00132	CcSEcCtD
Norethindrone—Drowsiness—Methotrexate—multiple sclerosis	8.9e-05	0.00131	CcSEcCtD
Norethindrone—Rash—Azathioprine—multiple sclerosis	8.89e-05	0.00131	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	8.88e-05	0.00131	CcSEcCtD
Norethindrone—Dermatitis—Azathioprine—multiple sclerosis	8.88e-05	0.00131	CcSEcCtD
Norethindrone—Depression—Methotrexate—multiple sclerosis	8.87e-05	0.00131	CcSEcCtD
Norethindrone—Headache—Azathioprine—multiple sclerosis	8.83e-05	0.0013	CcSEcCtD
Norethindrone—Renal failure—Methotrexate—multiple sclerosis	8.75e-05	0.00129	CcSEcCtD
Norethindrone—Immune system disorder—Prednisone—multiple sclerosis	8.64e-05	0.00127	CcSEcCtD
Norethindrone—Oedema—Triamcinolone—multiple sclerosis	8.6e-05	0.00127	CcSEcCtD
Norethindrone—Anaphylactic shock—Triamcinolone—multiple sclerosis	8.6e-05	0.00127	CcSEcCtD
Norethindrone—Anaphylactic shock—Methylprednisolone—multiple sclerosis	8.58e-05	0.00127	CcSEcCtD
Norethindrone—Insomnia—Prednisolone—multiple sclerosis	8.45e-05	0.00125	CcSEcCtD
Norethindrone—Alopecia—Prednisone—multiple sclerosis	8.45e-05	0.00125	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—multiple sclerosis	8.42e-05	0.00124	CcSEcCtD
Norethindrone—Hypersensitivity—Mitoxantrone—multiple sclerosis	8.39e-05	0.00124	CcSEcCtD
Norethindrone—Mental disorder—Prednisone—multiple sclerosis	8.38e-05	0.00124	CcSEcCtD
Norethindrone—Nausea—Azathioprine—multiple sclerosis	8.37e-05	0.00124	CcSEcCtD
Norethindrone—Skin disorder—Methylprednisolone—multiple sclerosis	8.33e-05	0.00123	CcSEcCtD
Norethindrone—Convulsion—Dexamethasone—multiple sclerosis	8.28e-05	0.00122	CcSEcCtD
Norethindrone—Convulsion—Betamethasone—multiple sclerosis	8.28e-05	0.00122	CcSEcCtD
Norethindrone—Asthenia—Mitoxantrone—multiple sclerosis	8.17e-05	0.00121	CcSEcCtD
Norethindrone—Haemoglobin—Methotrexate—multiple sclerosis	8.03e-05	0.00119	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—multiple sclerosis	7.99e-05	0.00118	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—multiple sclerosis	7.99e-05	0.00118	CcSEcCtD
Norethindrone—Oedema—Betamethasone—multiple sclerosis	7.8e-05	0.00115	CcSEcCtD
Norethindrone—Oedema—Dexamethasone—multiple sclerosis	7.8e-05	0.00115	CcSEcCtD
Norethindrone—Anaphylactic shock—Dexamethasone—multiple sclerosis	7.8e-05	0.00115	CcSEcCtD
Norethindrone—Anaphylactic shock—Betamethasone—multiple sclerosis	7.8e-05	0.00115	CcSEcCtD
Norethindrone—Insomnia—Triamcinolone—multiple sclerosis	7.77e-05	0.00115	CcSEcCtD
Norethindrone—Insomnia—Methylprednisolone—multiple sclerosis	7.76e-05	0.00115	CcSEcCtD
Norethindrone—Dyspepsia—Triamcinolone—multiple sclerosis	7.57e-05	0.00112	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—multiple sclerosis	7.55e-05	0.00112	CcSEcCtD
Norethindrone—Dyspepsia—Methylprednisolone—multiple sclerosis	7.55e-05	0.00111	CcSEcCtD
Norethindrone—Urticaria—Prednisolone—multiple sclerosis	7.43e-05	0.0011	CcSEcCtD
Norethindrone—Fatigue—Triamcinolone—multiple sclerosis	7.41e-05	0.00109	CcSEcCtD
Norethindrone—Fatigue—Methylprednisolone—multiple sclerosis	7.39e-05	0.00109	CcSEcCtD
Norethindrone—Vomiting—Mitoxantrone—multiple sclerosis	7.24e-05	0.00107	CcSEcCtD
Norethindrone—Immune system disorder—Methotrexate—multiple sclerosis	7.22e-05	0.00107	CcSEcCtD
Norethindrone—Convulsion—Prednisone—multiple sclerosis	7.21e-05	0.00106	CcSEcCtD
Norethindrone—Rash—Mitoxantrone—multiple sclerosis	7.18e-05	0.00106	CcSEcCtD
Norethindrone—Dermatitis—Mitoxantrone—multiple sclerosis	7.18e-05	0.00106	CcSEcCtD
Norethindrone—Headache—Mitoxantrone—multiple sclerosis	7.14e-05	0.00105	CcSEcCtD
Norethindrone—Alopecia—Methotrexate—multiple sclerosis	7.06e-05	0.00104	CcSEcCtD
Norethindrone—Insomnia—Betamethasone—multiple sclerosis	7.05e-05	0.00104	CcSEcCtD
Norethindrone—Insomnia—Dexamethasone—multiple sclerosis	7.05e-05	0.00104	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	7.04e-05	0.00104	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.01e-05	0.00104	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—multiple sclerosis	7e-05	0.00103	CcSEcCtD
Norethindrone—Hypersensitivity—Prednisolone—multiple sclerosis	6.89e-05	0.00102	CcSEcCtD
Norethindrone—Dyspepsia—Dexamethasone—multiple sclerosis	6.87e-05	0.00101	CcSEcCtD
Norethindrone—Dyspepsia—Betamethasone—multiple sclerosis	6.87e-05	0.00101	CcSEcCtD
Norethindrone—Urticaria—Triamcinolone—multiple sclerosis	6.83e-05	0.00101	CcSEcCtD
Norethindrone—Urticaria—Methylprednisolone—multiple sclerosis	6.81e-05	0.00101	CcSEcCtD
Norethindrone—Anaphylactic shock—Prednisone—multiple sclerosis	6.79e-05	0.001	CcSEcCtD
Norethindrone—Oedema—Prednisone—multiple sclerosis	6.79e-05	0.001	CcSEcCtD
Norethindrone—Abdominal pain—Methylprednisolone—multiple sclerosis	6.78e-05	0.001	CcSEcCtD
Norethindrone—Nausea—Mitoxantrone—multiple sclerosis	6.77e-05	0.000999	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	6.73e-05	0.000994	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	6.73e-05	0.000994	CcSEcCtD
Norethindrone—Fatigue—Betamethasone—multiple sclerosis	6.72e-05	0.000993	CcSEcCtD
Norethindrone—Fatigue—Dexamethasone—multiple sclerosis	6.72e-05	0.000993	CcSEcCtD
Norethindrone—Skin disorder—Prednisone—multiple sclerosis	6.6e-05	0.000974	CcSEcCtD
Norethindrone—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.38e-05	0.000942	CcSEcCtD
Norethindrone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.38e-05	0.000942	CcSEcCtD
Norethindrone—Hypersensitivity—Triamcinolone—multiple sclerosis	6.33e-05	0.000935	CcSEcCtD
Norethindrone—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.32e-05	0.000933	CcSEcCtD
Norethindrone—Urticaria—Dexamethasone—multiple sclerosis	6.2e-05	0.000915	CcSEcCtD
Norethindrone—Urticaria—Betamethasone—multiple sclerosis	6.2e-05	0.000915	CcSEcCtD
Norethindrone—Dizziness—Prednisolone—multiple sclerosis	6.18e-05	0.000913	CcSEcCtD
Norethindrone—Asthenia—Triamcinolone—multiple sclerosis	6.17e-05	0.000911	CcSEcCtD
Norethindrone—Abdominal pain—Betamethasone—multiple sclerosis	6.17e-05	0.00091	CcSEcCtD
Norethindrone—Abdominal pain—Dexamethasone—multiple sclerosis	6.17e-05	0.00091	CcSEcCtD
Norethindrone—Asthenia—Methylprednisolone—multiple sclerosis	6.15e-05	0.000909	CcSEcCtD
Norethindrone—Insomnia—Prednisone—multiple sclerosis	6.14e-05	0.000907	CcSEcCtD
Norethindrone—Pruritus—Triamcinolone—multiple sclerosis	6.08e-05	0.000898	CcSEcCtD
Norethindrone—Pruritus—Methylprednisolone—multiple sclerosis	6.07e-05	0.000896	CcSEcCtD
Norethindrone—Convulsion—Methotrexate—multiple sclerosis	6.03e-05	0.00089	CcSEcCtD
Norethindrone—Dyspepsia—Prednisone—multiple sclerosis	5.98e-05	0.000883	CcSEcCtD
Norethindrone—Rash—Prednisolone—multiple sclerosis	5.89e-05	0.00087	CcSEcCtD
Norethindrone—Dermatitis—Prednisolone—multiple sclerosis	5.89e-05	0.000869	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	5.88e-05	0.000868	CcSEcCtD
Norethindrone—Fatigue—Prednisone—multiple sclerosis	5.86e-05	0.000865	CcSEcCtD
Norethindrone—Headache—Prednisolone—multiple sclerosis	5.86e-05	0.000865	CcSEcCtD
Norethindrone—Dizziness—Triamcinolone—multiple sclerosis	5.68e-05	0.000839	CcSEcCtD
Norethindrone—Anaphylactic shock—Methotrexate—multiple sclerosis	5.68e-05	0.000838	CcSEcCtD
Norethindrone—Dizziness—Methylprednisolone—multiple sclerosis	5.67e-05	0.000837	CcSEcCtD
Norethindrone—Asthenia—Betamethasone—multiple sclerosis	5.6e-05	0.000826	CcSEcCtD
Norethindrone—Asthenia—Dexamethasone—multiple sclerosis	5.6e-05	0.000826	CcSEcCtD
Norethindrone—Gastrointestinal pain—Prednisone—multiple sclerosis	5.55e-05	0.00082	CcSEcCtD
Norethindrone—Nausea—Prednisolone—multiple sclerosis	5.55e-05	0.00082	CcSEcCtD
Norethindrone—Pruritus—Betamethasone—multiple sclerosis	5.52e-05	0.000815	CcSEcCtD
Norethindrone—Pruritus—Dexamethasone—multiple sclerosis	5.52e-05	0.000815	CcSEcCtD
Norethindrone—Skin disorder—Methotrexate—multiple sclerosis	5.51e-05	0.000814	CcSEcCtD
Norethindrone—Vomiting—Triamcinolone—multiple sclerosis	5.47e-05	0.000807	CcSEcCtD
Norethindrone—Vomiting—Methylprednisolone—multiple sclerosis	5.45e-05	0.000805	CcSEcCtD
Norethindrone—Rash—Triamcinolone—multiple sclerosis	5.42e-05	0.0008	CcSEcCtD
Norethindrone—Dermatitis—Triamcinolone—multiple sclerosis	5.41e-05	0.000799	CcSEcCtD
Norethindrone—Rash—Methylprednisolone—multiple sclerosis	5.41e-05	0.000798	CcSEcCtD
Norethindrone—Dermatitis—Methylprednisolone—multiple sclerosis	5.4e-05	0.000798	CcSEcCtD
Norethindrone—Urticaria—Prednisone—multiple sclerosis	5.4e-05	0.000797	CcSEcCtD
Norethindrone—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	5.39e-05	0.00902	CbGpPWpGaD
Norethindrone—Headache—Triamcinolone—multiple sclerosis	5.38e-05	0.000795	CcSEcCtD
Norethindrone—Headache—Methylprednisolone—multiple sclerosis	5.37e-05	0.000793	CcSEcCtD
Norethindrone—Abdominal pain—Prednisone—multiple sclerosis	5.37e-05	0.000793	CcSEcCtD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	5.21e-05	0.00872	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	5.21e-05	0.00872	CbGpPWpGaD
Norethindrone—Dizziness—Dexamethasone—multiple sclerosis	5.16e-05	0.000761	CcSEcCtD
Norethindrone—Dizziness—Betamethasone—multiple sclerosis	5.16e-05	0.000761	CcSEcCtD
Norethindrone—Insomnia—Methotrexate—multiple sclerosis	5.13e-05	0.000758	CcSEcCtD
Norethindrone—Nausea—Triamcinolone—multiple sclerosis	5.11e-05	0.000754	CcSEcCtD
Norethindrone—Nausea—Methylprednisolone—multiple sclerosis	5.09e-05	0.000752	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—multiple sclerosis	5.05e-05	0.000745	CcSEcCtD
Norethindrone—Hypersensitivity—Prednisone—multiple sclerosis	5e-05	0.000739	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—multiple sclerosis	5e-05	0.000738	CcSEcCtD
Norethindrone—Vomiting—Dexamethasone—multiple sclerosis	4.96e-05	0.000732	CcSEcCtD
Norethindrone—Vomiting—Betamethasone—multiple sclerosis	4.96e-05	0.000732	CcSEcCtD
Norethindrone—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	4.95e-05	0.00828	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	4.95e-05	0.00828	CbGpPWpGaD
Norethindrone—Rash—Betamethasone—multiple sclerosis	4.92e-05	0.000726	CcSEcCtD
Norethindrone—Rash—Dexamethasone—multiple sclerosis	4.92e-05	0.000726	CcSEcCtD
Norethindrone—Dermatitis—Betamethasone—multiple sclerosis	4.91e-05	0.000725	CcSEcCtD
Norethindrone—Dermatitis—Dexamethasone—multiple sclerosis	4.91e-05	0.000725	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.9e-05	0.000724	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—multiple sclerosis	4.89e-05	0.000723	CcSEcCtD
Norethindrone—Headache—Dexamethasone—multiple sclerosis	4.89e-05	0.000721	CcSEcCtD
Norethindrone—Headache—Betamethasone—multiple sclerosis	4.89e-05	0.000721	CcSEcCtD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	4.88e-05	0.00817	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	4.88e-05	0.00817	CbGpPWpGaD
Norethindrone—Asthenia—Prednisone—multiple sclerosis	4.87e-05	0.000719	CcSEcCtD
Norethindrone—Pruritus—Prednisone—multiple sclerosis	4.81e-05	0.000709	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.64e-05	0.000685	CcSEcCtD
Norethindrone—ALB—Platelet degranulation—PLEK—multiple sclerosis	4.64e-05	0.00776	CbGpPWpGaD
Norethindrone—Nausea—Dexamethasone—multiple sclerosis	4.63e-05	0.000684	CcSEcCtD
Norethindrone—Nausea—Betamethasone—multiple sclerosis	4.63e-05	0.000684	CcSEcCtD
Norethindrone—Urticaria—Methotrexate—multiple sclerosis	4.51e-05	0.000666	CcSEcCtD
Norethindrone—Dizziness—Prednisone—multiple sclerosis	4.49e-05	0.000663	CcSEcCtD
Norethindrone—Abdominal pain—Methotrexate—multiple sclerosis	4.49e-05	0.000663	CcSEcCtD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—PLEK—multiple sclerosis	4.42e-05	0.00739	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—CD28—multiple sclerosis	4.37e-05	0.00731	CbGpPWpGaD
Norethindrone—Vomiting—Prednisone—multiple sclerosis	4.32e-05	0.000638	CcSEcCtD
Norethindrone—Methyltestosterone—ALB—multiple sclerosis	4.28e-05	0.013	CrCbGaD
Norethindrone—Rash—Prednisone—multiple sclerosis	4.28e-05	0.000632	CcSEcCtD
Norethindrone—ABCB1—Allograft Rejection—C4A—multiple sclerosis	4.28e-05	0.00716	CbGpPWpGaD
Norethindrone—Dermatitis—Prednisone—multiple sclerosis	4.28e-05	0.000632	CcSEcCtD
Norethindrone—Headache—Prednisone—multiple sclerosis	4.25e-05	0.000628	CcSEcCtD
Norethindrone—Hypersensitivity—Methotrexate—multiple sclerosis	4.18e-05	0.000617	CcSEcCtD
Norethindrone—Asthenia—Methotrexate—multiple sclerosis	4.07e-05	0.000601	CcSEcCtD
Norethindrone—Nausea—Prednisone—multiple sclerosis	4.03e-05	0.000596	CcSEcCtD
Norethindrone—Pruritus—Methotrexate—multiple sclerosis	4.02e-05	0.000593	CcSEcCtD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	3.86e-05	0.00647	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	3.86e-05	0.00647	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	3.81e-05	0.00638	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	3.81e-05	0.00638	CbGpPWpGaD
Norethindrone—Dizziness—Methotrexate—multiple sclerosis	3.75e-05	0.000554	CcSEcCtD
Norethindrone—Vomiting—Methotrexate—multiple sclerosis	3.61e-05	0.000533	CcSEcCtD
Norethindrone—Rash—Methotrexate—multiple sclerosis	3.58e-05	0.000528	CcSEcCtD
Norethindrone—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	3.58e-05	0.00599	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	3.58e-05	0.00599	CbGpPWpGaD
Norethindrone—Dermatitis—Methotrexate—multiple sclerosis	3.58e-05	0.000528	CcSEcCtD
Norethindrone—Headache—Methotrexate—multiple sclerosis	3.56e-05	0.000525	CcSEcCtD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	3.53e-05	0.00591	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	3.53e-05	0.00591	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	3.49e-05	0.00584	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	3.49e-05	0.00584	CbGpPWpGaD
Norethindrone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	3.47e-05	0.0058	CbGpPWpGaD
Norethindrone—Nausea—Methotrexate—multiple sclerosis	3.37e-05	0.000498	CcSEcCtD
Norethindrone—ALB—Lipoprotein metabolism—APOE—multiple sclerosis	3.26e-05	0.00546	CbGpPWpGaD
Norethindrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	3.23e-05	0.00541	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	3.17e-05	0.00531	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	3.13e-05	0.00524	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	3.13e-05	0.00524	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—CD86—multiple sclerosis	3.12e-05	0.00521	CbGpPWpGaD
Norethindrone—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	3.01e-05	0.00504	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	2.99e-05	0.00501	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ZNF746—multiple sclerosis	2.97e-05	0.00497	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	2.77e-05	0.00463	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	2.77e-05	0.00463	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	2.73e-05	0.00457	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	2.73e-05	0.00457	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	2.72e-05	0.00455	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—PTBP1—multiple sclerosis	2.71e-05	0.00454	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—CCL5—multiple sclerosis	2.6e-05	0.00436	CbGpPWpGaD
Norethindrone—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.59e-05	0.00433	CbGpPWpGaD
Norethindrone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—multiple sclerosis	2.54e-05	0.00425	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—MYC—multiple sclerosis	2.49e-05	0.00417	CbGpPWpGaD
Norethindrone—Testosterone—ALB—multiple sclerosis	2.48e-05	0.00755	CrCbGaD
Norethindrone—ALB—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	2.38e-05	0.00399	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	2.36e-05	0.00394	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CD28—multiple sclerosis	2.29e-05	0.00383	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—CD80—multiple sclerosis	2.27e-05	0.0038	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	2.19e-05	0.00367	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	2.17e-05	0.00364	CbGpPWpGaD
Norethindrone—ALB—Lipid and lipoprotein metabolism—APOE—multiple sclerosis	2.17e-05	0.00363	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—APOE—multiple sclerosis	2.13e-05	0.00357	CbGpPWpGaD
Norethindrone—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.1e-05	0.00351	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CD40—multiple sclerosis	2.09e-05	0.0035	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	2.06e-05	0.00345	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—HNRNPA1—multiple sclerosis	2.06e-05	0.00344	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—U2AF2—multiple sclerosis	2.06e-05	0.00344	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	2.06e-05	0.00344	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL4—multiple sclerosis	2.05e-05	0.00344	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	2e-05	0.00335	CbGpPWpGaD
Norethindrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.99e-05	0.00333	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—TYK2—multiple sclerosis	1.92e-05	0.00321	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	1.88e-05	0.00315	CbGpPWpGaD
Norethindrone—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.87e-05	0.00313	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	1.81e-05	0.00303	CbGpPWpGaD
Norethindrone—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	1.81e-05	0.00302	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	1.79e-05	0.003	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MERTK—multiple sclerosis	1.72e-05	0.00287	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—CD58—multiple sclerosis	1.72e-05	0.00287	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SELPLG—multiple sclerosis	1.72e-05	0.00287	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	1.7e-05	0.00284	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	1.66e-05	0.00278	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	1.66e-05	0.00278	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.64e-05	0.00275	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.64e-05	0.00275	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CD86—multiple sclerosis	1.63e-05	0.00273	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—ICAM1—multiple sclerosis	1.63e-05	0.00273	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ZFP36L1—multiple sclerosis	1.63e-05	0.00272	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL10—multiple sclerosis	1.6e-05	0.00268	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	1.6e-05	0.00268	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL4—multiple sclerosis	1.56e-05	0.00261	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—LINGO1—multiple sclerosis	1.54e-05	0.00258	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	1.53e-05	0.00255	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	1.52e-05	0.00255	CbGpPWpGaD
Norethindrone—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.52e-05	0.00254	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—CCL2—multiple sclerosis	1.46e-05	0.00244	CbGpPWpGaD
Norethindrone—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.45e-05	0.00242	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—FAS—multiple sclerosis	1.44e-05	0.0024	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	1.43e-05	0.00239	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	1.41e-05	0.00236	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	1.36e-05	0.00228	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TAGAP—multiple sclerosis	1.34e-05	0.00224	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—VDR—multiple sclerosis	1.3e-05	0.00217	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	1.3e-05	0.00217	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	1.29e-05	0.00216	CbGpPWpGaD
Norethindrone—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	1.26e-05	0.00211	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—PABPC1—multiple sclerosis	1.26e-05	0.00211	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IFNG—multiple sclerosis	1.24e-05	0.00208	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—MAPK1—multiple sclerosis	1.22e-05	0.00204	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.21e-05	0.00203	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—SRM—multiple sclerosis	1.2e-05	0.00201	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CD80—multiple sclerosis	1.19e-05	0.00199	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.18e-05	0.00198	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.18e-05	0.00198	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.17e-05	0.00196	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—S1PR1—multiple sclerosis	1.17e-05	0.00196	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	1.16e-05	0.00194	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—RPL5—multiple sclerosis	1.14e-05	0.0019	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GPC5—multiple sclerosis	1.14e-05	0.0019	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—POMC—multiple sclerosis	1.11e-05	0.00186	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL1B—multiple sclerosis	1.11e-05	0.00185	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL2—multiple sclerosis	1.1e-05	0.00185	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.06e-05	0.00178	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.06e-05	0.00178	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.06e-05	0.00177	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PLEK—multiple sclerosis	1.06e-05	0.00177	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	1.03e-05	0.00173	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RGS1—multiple sclerosis	9.94e-06	0.00166	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	9.87e-06	0.00165	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	9.86e-06	0.00165	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	9.59e-06	0.0016	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GPR65—multiple sclerosis	9.42e-06	0.00158	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	9.42e-06	0.00158	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—IL6—multiple sclerosis	9.38e-06	0.00157	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.17e-06	0.00154	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	8.79e-06	0.00147	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.69e-06	0.00145	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—SRM—multiple sclerosis	8.69e-06	0.00145	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL13—multiple sclerosis	8.62e-06	0.00144	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCR1—multiple sclerosis	8.62e-06	0.00144	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	8.47e-06	0.00142	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	8.47e-06	0.00142	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	8.4e-06	0.00141	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL2—multiple sclerosis	8.37e-06	0.0014	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	8.28e-06	0.00139	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—POMC—multiple sclerosis	8.05e-06	0.00135	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	8.04e-06	0.00135	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TNF—multiple sclerosis	8.03e-06	0.00134	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	7.97e-06	0.00133	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GPC5—multiple sclerosis	7.74e-06	0.0013	CbGpPWpGaD
Norethindrone—ALB—Metabolism—SRM—multiple sclerosis	7.48e-06	0.00125	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SELE—multiple sclerosis	7.47e-06	0.00125	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—TGFB1—multiple sclerosis	7.38e-06	0.00123	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.25e-06	0.00121	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	7.15e-06	0.0012	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	7.09e-06	0.00119	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.05e-06	0.00118	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	7.03e-06	0.00118	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—SRM—multiple sclerosis	6.72e-06	0.00112	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—SRM—multiple sclerosis	6.55e-06	0.0011	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	6.53e-06	0.00109	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL6—multiple sclerosis	6.48e-06	0.00108	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—RRM1—multiple sclerosis	6.42e-06	0.00107	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.41e-06	0.00107	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	6.38e-06	0.00107	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	6.35e-06	0.00106	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—VDR—multiple sclerosis	6.26e-06	0.00105	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—POMC—multiple sclerosis	6.22e-06	0.00104	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCL3—multiple sclerosis	6.14e-06	0.00103	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	6.12e-06	0.00102	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	6.12e-06	0.00102	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—TNF—multiple sclerosis	6.1e-06	0.00102	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTGER4—multiple sclerosis	5.91e-06	0.000989	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCR3—multiple sclerosis	5.71e-06	0.000956	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CD28—multiple sclerosis	5.66e-06	0.000947	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.62e-06	0.00094	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GPC5—multiple sclerosis	5.6e-06	0.000937	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCR2—multiple sclerosis	5.55e-06	0.00093	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—ITGA4—multiple sclerosis	5.4e-06	0.000903	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IFNB1—multiple sclerosis	5.36e-06	0.000897	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP24A1—multiple sclerosis	5.27e-06	0.000882	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP27B1—multiple sclerosis	5.27e-06	0.000882	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—MYC—multiple sclerosis	5.17e-06	0.000864	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.15e-06	0.000862	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	5.15e-06	0.000862	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CNR1—multiple sclerosis	5.13e-06	0.000858	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GPC5—multiple sclerosis	4.82e-06	0.000807	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	4.73e-06	0.000792	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	4.73e-06	0.000792	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—RRM1—multiple sclerosis	4.64e-06	0.000776	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.62e-06	0.000774	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP24A1—multiple sclerosis	4.62e-06	0.000773	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP27B1—multiple sclerosis	4.62e-06	0.000773	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL10—multiple sclerosis	4.62e-06	0.000772	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GPC5—multiple sclerosis	4.33e-06	0.000724	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GPC5—multiple sclerosis	4.22e-06	0.000707	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	4.19e-06	0.000702	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SRM—multiple sclerosis	4.04e-06	0.000676	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CD86—multiple sclerosis	4.04e-06	0.000675	CbGpPWpGaD
Norethindrone—ALB—Metabolism—RRM1—multiple sclerosis	3.99e-06	0.000668	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCL5—multiple sclerosis	3.97e-06	0.000665	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.74e-06	0.000626	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2RA—multiple sclerosis	3.69e-06	0.000617	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—BCHE—multiple sclerosis	3.69e-06	0.000617	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SPP1—multiple sclerosis	3.68e-06	0.000616	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—RRM1—multiple sclerosis	3.59e-06	0.0006	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCR5—multiple sclerosis	3.58e-06	0.000599	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2RA—multiple sclerosis	3.53e-06	0.00059	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—RRM1—multiple sclerosis	3.5e-06	0.000586	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	3.27e-06	0.000547	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—APOE—multiple sclerosis	3.26e-06	0.000545	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.23e-06	0.00054	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.22e-06	0.000539	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	3.21e-06	0.000537	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.16e-06	0.000529	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.1e-06	0.000519	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.01e-06	0.000503	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CD80—multiple sclerosis	2.94e-06	0.000493	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.85e-06	0.000476	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.85e-06	0.000476	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—POMC—multiple sclerosis	2.8e-06	0.000468	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.78e-06	0.000466	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCL2—multiple sclerosis	2.74e-06	0.000458	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—BCHE—multiple sclerosis	2.66e-06	0.000446	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.66e-06	0.000446	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.6e-06	0.000435	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MYC—multiple sclerosis	2.49e-06	0.000416	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TYK2—multiple sclerosis	2.49e-06	0.000416	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.39e-06	0.0004	CbGpPWpGaD
Norethindrone—ALB—Metabolism—BCHE—multiple sclerosis	2.29e-06	0.000384	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—APOE—multiple sclerosis	2.22e-06	0.000371	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.18e-06	0.000365	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2—multiple sclerosis	2.16e-06	0.000362	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.16e-06	0.000361	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2—multiple sclerosis	2.07e-06	0.000346	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—BCHE—multiple sclerosis	2.06e-06	0.000345	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.02e-06	0.000338	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—BCHE—multiple sclerosis	2.01e-06	0.000336	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—multiple sclerosis	1.96e-06	0.000328	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—POMC—multiple sclerosis	1.9e-06	0.000319	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STAT3—multiple sclerosis	1.74e-06	0.000291	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ALB—multiple sclerosis	1.74e-06	0.000291	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TGFB1—multiple sclerosis	1.69e-06	0.000282	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MAPK1—multiple sclerosis	1.65e-06	0.000277	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MYC—multiple sclerosis	1.62e-06	0.000271	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TGFB1—multiple sclerosis	1.61e-06	0.00027	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—APOE—multiple sclerosis	1.6e-06	0.000268	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MAPK1—multiple sclerosis	1.58e-06	0.000265	CbGpPWpGaD
Norethindrone—ALB—Metabolism—APOE—multiple sclerosis	1.38e-06	0.000231	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—POMC—multiple sclerosis	1.38e-06	0.00023	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ALB—multiple sclerosis	1.26e-06	0.00021	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—APOE—multiple sclerosis	1.24e-06	0.000207	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.24e-06	0.000207	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6—multiple sclerosis	1.22e-06	0.000203	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—APOE—multiple sclerosis	1.21e-06	0.000202	CbGpPWpGaD
Norethindrone—ALB—Metabolism—POMC—multiple sclerosis	1.19e-06	0.000198	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—POMC—multiple sclerosis	1.06e-06	0.000178	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—POMC—multiple sclerosis	1.04e-06	0.000174	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ALB—multiple sclerosis	9.7e-07	0.000162	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ALB—multiple sclerosis	9.47e-07	0.000158	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—APOE—multiple sclerosis	7.45e-07	0.000125	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—POMC—multiple sclerosis	6.4e-07	0.000107	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ALB—multiple sclerosis	5.84e-07	9.76e-05	CbGpPWpGaD
